### Poster Session 66

**Localised prostate cancer: Innovative strategies in active surveillance and focal therapy**

**Location:** Room Madrid (Hall B2, level 0)

**Chairs:**
- J-L. Descotes, Grenoble (FR)
- G. Giannarini, Udine (IT)

**Aims and objectives of this presentation**

The session focuses on novel strategies in active surveillance and focal therapy for prostate cancer.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

#### 829

**Multiparametric MRI features that poorer mid-term outcomes in active surveillance patients**

**By:** Sanguedolce F.¹, Petralia G.², Sokhi H.³, Tagliabue E.⁴, Anyamene N.⁵, Hellawell G.⁶, Padhani A.R.⁷

**Institutes:**
- Northampton General Hospital NHS Trust, Dept. of Urology, Northampton, United Kingdom,
- Istituto Europeo di Oncologia, Dept. of Urology, Milan, Italy,
- Hillingdon & Mount Vernon Hospital, Dept. of Radiology, London, United Kingdom,
- Istituto Europeo di Oncologia, Division of Epidemiology and Biostatistics, Milan, Italy,
- Mount Vernon Hospital, Dept. of Oncology, London, United Kingdom,
- Northwick Park Hospital, Dept. of Urology, London, United Kingdom,
- Mount Vernon Cancer Centre, Paul Strickland Scanner Centre, London, United Kingdom

#### 830

**Multiparametric MRI predicts adverse pathological prostate cancer features in patients eligible for active surveillance**

**By:** Boesen L.¹, Nørgaard N.¹, Loegager V.², Jakobsen J.¹, Bisbjerg R.¹, Thomsen H.², Jakobsen H.¹

**Institutes:**
- Herlev Hospital, Dept. of Urology, Herlev, Denmark,
- Herlev Hospital, Dept. of Radiology, Herlev, Denmark

#### 831

**Multiparametric-MRI, PCA3 and PHI in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance**

**By:** Porpiglia F.¹, De Luca S.¹, Manfredi M.¹, Mele F.¹, Russo F.², Sottile A.³, Serra N.¹, Fiori C.¹

**Institutes:**
- San Luigi Gonzaga Hospital, University of Turin, Dept. of Urology, Orbassano, Italy,
- Candiolo Cancer Institute, Dept. of Radiology, Candiolo, Italy,
- Candiolo Cancer Institute, Dept. of Laboratory Medicine, Candiolo, Italy

#### 832

**Molecular profiling of prostate cancer derived from serial MRI targeted prostate biopsy in men on active surveillance**

**By:** Palapattu G.², Cani A.K.³, Hoevelson D.³, Mehra R.³, Montgomery J.S.¹, Morgan T.¹, Salami S.¹, Tomlins S.A.³, Marks L.S.⁴

**Institutes:**
- University Of Michigan, Dept. of Urology, Ann Arbor, United States of America,
- University of Michigan, Dept. of Urology, Ann Arbor, United States of America,
- University of Michigan, Dept. of Pathology, Ann Arbor, United States of America,
- University of California, Los Angeles, Dept. of Urology, Los Angeles, United States of America

#### 833

**Transurethral resection of the prostate for patients with Gleason score 6 prostate cancer and symptomatic prostatic enlargement: A risk-adaptive strategy for the era of active surveillance**

**By:** Koo K.C.¹, Lee K.S.¹, Lee D.H.², Rha K.H.¹, Hong S.J.¹, Bang W.J.³, Chung B.H.¹

**Institutes:**
- Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea,
- Busan
834

**Standardization in definitions in focal therapy for prostate cancer: Report from a Delphi consensus project**

By: Postema A.¹, De Reijke T.¹, Ukimura O.², Van Den Bos W.¹, De La Rosette J.¹

**Institutes:** AMC University Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²Keck School of Medicine, University of Southern California, Dept. of Urology, Los Angeles, United States of America

---

835

**High intensity focused ultrasound hemiablation versus MRI guided ‘lesion only’ ablation of prostate cancer – genito-urinary functional outcomes and complications**


**Institutes:** Institute Mutualiste Montsouris, Dept. of Urology, Paris, France

---

836

**MRI-US fusion guided high-intensity focused ultrasound with Focal-One® system: Impact on PSA, complications and genito-urinary functions during initial experience**


**Institutes:** Institute Mutualiste Montsouris, Dept. of Urology, Paris, France

---

837

**Intraprostatic spatial distribution of prostate cancer: A pre versus post HIFU comparison based on 15,000 biopsies**

By: Thüroff S.¹, Chaussy C.²

**Institutes:** ¹Klinikum Harlaching, Dept. of Urology, Munich, Germany, ²St. Josephs Klinik, Dept. of Urology, Regensburg, Germany

---

838

**Magnetic resonance imaging-guided transurethral ultrasound prostate ablation in patients with localized prostate cancer: 12-Month outcomes of a prospective phase I clinical trial**

By: Billia M.¹, Pahernik S.², Relle J.³, Popeneciu I.V.², Kuru T.³, Hafron J.³, Romagnoli C.², Burtnyk M.⁵, Schlemmer H-P.², Chin J.L.⁴

**Institutes:** London Health Sciences Center University of Western Ontario, Dept. of Urology and Radiology, London, Canada, ²German Cancer Research Center (DKFZ), Dept. of Urology and Radiology, Heidelberg, Germany, ³Beaumont Health System, Dept. of Urology and Radiology, Royal Oak, United States of America, ⁴London Health Sciences Center University of Western Ontario, Dept. of Urology and Radiology, London Ontario, Canada, ⁵Profound Medical Inc., Dept. of Engineering, Toronto, Canada

---

839

**A prospective development study evaluating focal irreversible electroporation in men with localised prostate cancer: The NEAT trial**

By: Valerio M.¹, Dickinson L.¹, Ali A.², Ramachadran N.³, Donaldson I.¹, McCartan N.¹, Freeman A.⁴, Ahmed H.¹, Emberton M.¹

**Institutes:** ¹UCLH NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ²UCL, Dept. of Mental Health Sciences, London, United Kingdom, ³UCLH NHS Foundation Trust, Dept. of Radiology, London, United Kingdom, ⁴UCLH NHS Foundation Trust, Dept. of Pathology, London, United Kingdom

---

840

**Can small lesions of Gleason 3+4 be left untreated in focal therapy? Analysis of radical prostatectomy specimens**

By: Kanao K., Kajikawa K., Kobayashi I., Muramatsu H., Morinaga S., Nishikawa G., Yoshizawa T., Kato Y., Watanabe M., Nakamura K., Sumitomo M.

**Institutes:** Aichi Medical University, Dept. of Urology, Nagakute, Japan

---

841

**Medium term outcomes following focal HIFU for the treatment of non-metastatic prostate cancer: A UK registry analysis of 625 cases**

By: Guillamier S.¹, Hamid S.¹, Charman S.¹, Van Der Meulen J.¹, McCartan N.¹, Shah K.¹, Hindley R.², Nigam R.³, Dudderidge T.⁴, Afzal N.⁵, Cornaby A.⁶, Lewi H.⁶, Persad R.⁷, Moore C.¹, Virdi J.⁸, Arya
An open, single dose, anti-tumour effect study of 2-hydroxyflutamide as a controlled release product (Liproca® Depot) injected into the prostate in patients with localized prostate cancer

By: Tammela T.¹, Bjartell A.², Häggman M.³

Institutes: ¹Tampere University Hospital, Dept. of Surgery, Tampere, Finland, ²Skåne University Hospital, Dept. of Urology, Malmö, Sweden, ³Uppsala University Hospital, Dept. of Urology, Uppsala, Sweden